Healthium Medtech has filed draft red herring prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI) for an Initial Public Offering (IPO). The IPO comprises fresh issuance of equity shares worth Rs 390 crore and an offer-for-sale of 3.91 crore equity shares by existing shareholders and promoters.
Proceeds from the fresh issue to the tune of Rs 50.09 crore will be utilized to repay debt, Rs 179.46 crore will be invested into its subsidiaries Sironix, Clinisupplies, and Quality Needles, and Rs 58 crore will be used for acquisition and other strategic initiatives. ICICI Securities, CLSA India, Credit Suisse Securities India, and Nomura Financial Advisory and Securities India are lead managers to the issue.
Healthium Medtech is a global Medtech company focused on products used in surgical, post-surgical, and chronic care. It operates across three key markets, India, the UK, and the rest of the world, and four focus areas, namely, advanced surgery, urology, arthroscopy, and wound care.